Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 1/20 | 0.64 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | STS | P08842 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31615814 | 0.94 | P2RY14 (0.59) | P2RY14NAMPTMAPTSTSGPR119 | |
| SCHEMBL4407036 | 0.89 | NAMPT (0.60) | P2RY14NAMPTMAPTSTSGPR119 | |
| SCHEMBL22059421 | 0.86 | RORC (0.57) | P2RY14MAPTSTSGPR119KDM4E | |
| SCHEMBL2594236 | 0.86 | NAMPT (0.60) | P2RY14NAMPTMAPTGPR119KDM4E | |
| SCHEMBL18805528 | 0.86 | NAMPT (0.60) | P2RY14NAMPTMAPTGPR119KDM4E | |
| SCHEMBL21425200 | 0.86 | MAPT (0.56) | P2RY14NAMPTMAPTSTSGPR119 | |
| SCHEMBL12117456 | 0.85 | GPR119 (0.65) | NAMPTMAPTGPR119KDM4ETHRB | |
| SCHEMBL3854559 | 0.85 | NAMPT (0.61) | P2RY14NAMPTMAPTSTSGPR119 | |
| SCHEMBL4183397 | 0.84 | GPR119 (0.61) | P2RY14NAMPTMAPTGPR119KDM4E | |
| SCHEMBL23211982 | 0.84 | MAPT (0.56) | P2RY14MAPTSTSGPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027615-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2021-07-21 | — | — | EP | disclosed |
| WO-2021142420-A1 | PYRAZOLO[1,5-a]PYRIMIDIN-7(4H)-ONE INHIBITORS OF DYNEIN | KAPOOR TARUN M (US) | 2021-07-15 | — | — | WO | disclosed |
| WO-2021142420-A1 | PYRAZOLO[1,5-a]PYRIMIDIN-7(4H)-ONE INHIBITORS OF DYNEIN | KAPOOR TARUN M (US) | 2021-07-15 | — | — | WO | disclosed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | P2RY14 154/4885NAMPT 273/4885MAPT 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.